Your browser doesn't support javascript.
loading
Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.
Nakasuka, Takamasa; Ichihara, Eiki; Makimoto, Go; Maeda, Yoshinobu; Kiura, Katsuyuki.
Affiliation
  • Nakasuka T; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
  • Ichihara E; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan. Electronic address: ichiha-e@md.okayama-u.ac.jp.
  • Makimoto G; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Maeda Y; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Kiura K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
J Thorac Oncol ; 14(8): e168-e169, 2019 08.
Article in En | MEDLINE | ID: mdl-31345339
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Carbazoles / Protein Kinase Inhibitors / Bevacizumab / Adenocarcinoma of Lung / Lung Neoplasms Limits: Humans Language: En Journal: J Thorac Oncol Year: 2019 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Carbazoles / Protein Kinase Inhibitors / Bevacizumab / Adenocarcinoma of Lung / Lung Neoplasms Limits: Humans Language: En Journal: J Thorac Oncol Year: 2019 Document type: Article Affiliation country: Country of publication: